David R. Bauer

Davis Polk advised the representatives of the underwriters in connection with the $230 million initial public offering of 12,105,263 shares of common stock of Generation Bio Co., which…

Davis Polk advised the sales agent in connection with an SEC-registered at-the-market offering by Applied Therapeutics, Inc. of shares of its common stock for up to a maximum offering…

Davis Polk is advising Novo Nordisk A/S on its acquisition of Corvidia Therapeutics Inc. for an upfront payment of $725 million in cash. Total payments to Corvidia Therapeutics shareholders…

Davis Polk advised the underwriters in connection with the $487 million SEC-registered initial public offering by Legend Biotech Corporation of 21,188,750 American Depositary Shares, each…

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by NuVasive, Inc. of $400 million aggregate principal amount of its 1.000%…

Davis Polk advised Penumbra, Inc. on its SEC-registered follow-on public offering of 865,963 shares of common stock for an aggregate price to the public of approximately $143.75 million,…

Davis Polk advised the representatives of the underwriters in connection with the $70 million follow-on public offering of 5,000,000 shares of common stock of TransMedics Group, Inc…

Davis Polk advised the representatives of the underwriters in connection with the $60 million SEC-registered follow-on offering of ordinary shares of Gamida Cell Ltd. The ordinary…

Davis Polk advised ADC Therapeutics SA on its SEC-registered initial public offering of 14,082,475 common shares, which included the exercise in full by the underwriters of their option to…

Davis Polk advised the underwriters in connection with the public offering of 2,369,668 shares of common stock of Insulet Corporation. The offering resulted in approximately $500…